FDA clears MC3 Cardiopulmonary’s Crescent ECMO catheter

MC3 recently received FDA clearance for its Crescent Jugular Dual Lumen Catheter designed for extracorporeal membrane oxygenation.

The catheter is a single-use, dual lumen catheter that is placed through the jugular vein and connected to an ECMO system that removed carbon dioxide and reinfuses oxygenated blood. Its design minimizes recirculation while allowing for smooth insertion, visible location and durable placement, according to MC3.

“There is an underserved population suffering with lung failure around the world, and the introduction of our Crescent catheter means new options for surgeons and their patients,” Scott Merz, CEO of MC3 Cardiopulmonary, said in a press release. “Until recently, mechanical ventilation with intubation was the last line of defense for millions of patients around the world each year. Due to the advancements in technology available in Crescent, we can now consider cannulating the sickest of these patients instead of intubating them. Crescent is the lifeline between the patient and the ECMO system, and we believe vascular access is one of the most important technology segments in healthcare today. Our shared vision with the clinical community is to take standardized ECMO care from possibility to reality.”

MC3’s Crescent Jugular Dual Lumen Catheters offers venous drainage and reinfusion of blood through the jugular vein and is indicated for use in patients that have acute respiratory failure who also need vino-venous extracorporeal membrane oxygenation.